Arcutis Biotherapeutics (ARQT) Common Equity (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Common Equity of $189.6 million for Q1 2026, up 32.94% year-over-year from $142.7 million in Q1 2025, and little changed quarter-over-quarter from $189.5 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Common Equity (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $189.6 million for Q1 2026.
- In Q1 2026, Common Equity rose 32.94% year-over-year to $189.6 million; the TTM figure through Mar 2026 stood at $189.6 million (up 32.94% YoY), while the FY2025 annual figure was $189.5 million, up 20.27% from the prior year.
- Common Equity for Q1 2026 stood at $189.6 million, roughly flat from $189.5 million in the prior quarter.
- The five-year high for Common Equity was $270.8 million in Q3 2022, with the low at $46.7 million in Q3 2023.
- The 5-year median for Common Equity is $158.1 million (2025), against an average of $166.4 million.
- The sharpest annual moves came in 2023 and 2024: Common Equity plunged 82.75% in 2023, then soared 235.3% in 2024.
- Arcutis Biotherapeutics' Common Equity stood at $209.6 million in 2022, then plunged by 57.69% to $88.7 million in 2023, then surged by 77.68% to $157.5 million in 2024, then advanced by 20.27% to $189.5 million in 2025, then advanced by 0.09% to $189.6 million in 2026.
- Business Quant data shows ARQT's Common Equity at $189.6 million in Q1 2026, $189.5 million in Q4 2025, and $158.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 220.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 220.58 Mn |
| Mar 31, 2026 | 189.65 Mn |
| Dec 31, 2025 | 189.48 Mn |
| Sep 30, 2025 | 158.07 Mn |
| Jun 30, 2025 | 138.97 Mn |
| Mar 31, 2025 | 142.66 Mn |
| Dec 31, 2024 | 157.54 Mn |
| Sep 30, 2024 | 156.64 Mn |
| Jun 30, 2024 | 186.43 Mn |
| Mar 31, 2024 | 224.94 Mn |
| Dec 31, 2023 | 88.67 Mn |
| Sep 30, 2023 | 46.72 Mn |
| Jun 30, 2023 | 80.51 Mn |
| Mar 31, 2023 | 139.73 Mn |
| Dec 31, 2022 | 209.58 Mn |
| Sep 30, 2022 | 270.77 Mn |
| Jun 30, 2022 | 195.38 Mn |
| Mar 31, 2022 | 253.77 Mn |
| Dec 31, 2021 | 297.68 Mn |
| Sep 30, 2021 | 363.00 Mn |